Neoadjuvant Treatment of Ovarian Cancer With Fluazoparib in Combination With Apatinib
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
In this study, investigators propose to use fluzoparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency HRDpositive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this 'de-chemotherapy' regimen as neoadjuvant therapy for advanced ovarian cancer, and to conduct genetically related subgroup analyses, to guide the precision therapy and provide a new therapeutic option for HRD-positive patients with advanced ovarian cancer. To provide a new treatment option In order to increase the R0 resection rate of surgery and reduce chemotherapy resistance, thus improving the prognosis and prolonging the survival of patients.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
apatinib Drug Therapy Neoadjuvant Therapy Opiate Substitution Treatment Preoperative Period